AEON Biopharma to Join the H.C. Wainwright 26th Annual Global Investment Conference
AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical firm committed to developing a botulinum toxin complex for various therapeutic applications, has announced its participation in an important investment conference. Marc Forth, AEON’s President and Chief Executive Officer, will deliver a detailed corporate overview during the event. This presentation is set for September 11, 2024, at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference.
In addition to the presentation, Marc Forth will hold one-on-one meetings with institutional investors throughout the conference. Interested investors are encouraged to reach out to their H.C. Wainwright representatives to arrange these meetings.
For those who cannot attend in person, a live webcast of the event will be accessible through the conference host, allowing a wider audience to engage with AEON's corporate presentation.
About AEON Biopharma
AEON is leading the way in biopharmaceutical innovation, with a focus on its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection. The company aims to tackle debilitating medical conditions, particularly within the neurosciences field. Importantly, ABP-450 is equivalent to the botulinum toxin complex currently marketed for cosmetic purposes by Evolus under the brand name Jeuveau.
The production of ABP-450 follows rigorous Good Manufacturing Practice (cGMP) standards and takes place in a facility that is approved by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency. Additionally, ABP-450 has received biosimilar approval in Mexico and India. AEON possesses exclusive rights for the development and distribution of ABP-450 for therapeutic use in the United States, Canada, the European Union, the United Kingdom, and several other international markets.
AEON has built a highly experienced management team with extensive backgrounds in biopharmaceuticals and expertise in the development and commercialization of botulinum toxins, positioning the company strongly for its future initiatives.
For further details about AEON Biopharma, please visit www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Frequently Asked Questions
1. What is the primary focus of AEON Biopharma?
AEON Biopharma is dedicated to developing its proprietary botulinum toxin complex, ABP-450, with a focus on addressing debilitating medical conditions, especially in the neurosciences sector.
2. When will AEON Biopharma present at the H.C. Wainwright Conference?
AEON Biopharma's presentation is scheduled for September 11, 2024, at 1:30 PM ET during the H.C. Wainwright 26th Annual Global Investment Conference.
3. How can investors participate in meetings with AEON?
Institutional investors who wish to meet with AEON during the conference should contact their H.C. Wainwright representatives to set up one-on-one meetings.
4. Is the ABP-450 product approved in any regions?
Yes, ABP-450 has received biosimilar approval in Mexico and India, and its manufacturing adheres to strict regulatory standards.
5. How can investors learn more about AEON Biopharma?
Investors can find additional information about AEON Biopharma by visiting their official website at www.aeonbiopharma.com.
